Catalent
CTLT
#1601
Rank
โ‚น909.86 B
Marketcap
โ‚น5,013
Share price
-0.85%
Change (1 day)
76.70%
Change (1 year)
Catalent is an American pharmaceutical contract research and development company.

P/E ratio for Catalent (CTLT)

P/E ratio as of November 2024 (TTM): -46.2

According to Catalent's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -46.1899. At the end of 2022 the company had a P/E ratio of 19.8.

P/E ratio history for Catalent from 2014 to 2023

PE ratio at the end of each year

Year P/E ratio Change
202219.8-49.36%
202139.2-31.53%
202057.2-13.67%
201966.2112.43%
201831.2-56.74%
201772.197.82%
201636.4166.37%
201513.7-76.5%
201458.2

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
45.6-198.79%๐Ÿ‡บ๐Ÿ‡ธ USA
-20.3-55.98%๐Ÿ‡บ๐Ÿ‡ธ USA
-86.7 87.63%๐Ÿ‡ฎ๐Ÿ‡ช Ireland
2.97-106.44%๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.